STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

GHK-Cu

Also known as

Copper peptide · GHK copper · glycyl-L-histidyl-L-lysine copper · GHK-Cu copper tripeptide · copper tripeptide-1 (cosmetic INCI contexts) · Gly-His-Lys-Cu · copper tripeptide-1

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Lots of talk Mixed Topical / SubQ Skin, hair & tissue remodeling

Mixed — topical stays on skin/scalp; injectable charts treat it as whole-body remodeling.

What people say GHK-Cu is the copper-bound Gly-His-Lys tripeptide. Topical skin evidence and gray-market injectable GLOW/KLOW discussion are different product, route and evidence contexts. Doses people talk about
Solo self-report800 mcg, then 1 mg SC

One user reported skin improvement by week 4 at 800 mcg, then “copper uglies” after moving to 1 mg and improvement after stopping.

GLOW self-log1.5 mg, 6 days/week

One author reported “uglies” after two weeks, paused two weeks, then later used separate GHK-Cu four nights weekly with dose changes and multiple co-interventions.

Repeated solo range~0.5–2 mg/day SC

Common chart band preserved from the original record; individual reports include both no reaction and significant skin or site effects inside it.

Solo GHK-Cu and fixed-ratio blends are not the same exposure. These amounts are reports, not a loading sequence or zinc recommendation.

Half-life & effect duration

Half-life in the body
  • Common community estimateAbout 30 minutes
  • Other injection estimatesAbout 105 minutes or 2–4 hours
Felt duration people report
  • ImmediatelySite sensations, or none; blend pain lasted much of 2 days in one account
  • Skin reportsImprovement by 4 weeks in one account; worsening after a change in amount
  • Other accountsCopper uglies after about 2 weeks, no reaction, or lost benefit during breaks
Timing context & sources
How it may feel Injectable reports range from no site reaction to burning, welts or hours of pain. Skin improvement is usually described after weeks, while “copper uglies” can appear early; stopping or restarting confounds the clock.
Cycles people discuss Injectable calendars include roughly 30-day, 4–8-week and GLOW/KLOW blocks with breaks; topicals are often continuous. These are community patterns, not proven exposure or tolerance rules. Timing Human intact-complex PK remains uncharacterized in the checked evidence. Community half-life figures conflict; skin and hair changes unfold over weeks to months and do not measure parent-peptide clearance. Around the dose Clock: Daily. Topical AM or PM with skincare; injectable often morning with Glow/KLOW. Stacks GLOW and KLOW lock GHK-Cu into blends with BPC-157, TB-500 and sometimes KPV. Separate vials and topicals create different amounts, clocks and attribution problems. Access talk Not on the July 23, 2026 ballot: PCAC that week voted BPC-157, KPV, TB-500, MOTS-c (then others the next day). GHK-Cu was a later, separate review. Labs people mention Copper panel talk: Serum copper, ceruloplasmin, and zinc are the labs 2026 GHK posts actually name. Watch for Injection site: Redness, warmth, swelling, bruise, itch, lingering ache, or blue-tint mark — among the most reported practical issues; many call GHK-Cu a burning/stinging pin.
Related
BPC-157TB-500AHK-CuKPV

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

No human intact-GHK-Cu half-life was established by the checked evidence.

Community figures of ~30 minutes, ~105 minutes and ~2–4 hours circulate without a consistently identified analyte, species, route or formulation.

Topical efficacy studies do not measure systemic intact-complex PK; free GHK and copper-bound GHK-Cu may not share kinetics.

Felt duration people report

Site sensations can be immediate or absent; skin changes and “copper uglies” are reported on a weeks-long clock.

One user reported improvement by four weeks at 800 mcg and worsening after 1 mg. Another saw “uglies” after two weeks on 1.5 mg six days weekly, while others reported no reaction or benefit loss during breaks.

Unverified products, self-selected reporting, blends, skincare and zinc changes; no single-dose cosmetic-effect duration is established.

  • Ghkcu experience (opens in a new tab)Post and visible reply chain: ooticklemypickle at week 2 on KLOW; Ok-Figures reported 800 mcg, four-week improvement, worsening after 1 mg, stopping and planned restart.Unverified blend/product, no images or objective measures, other interventions and incomplete follow-up. Advice in replies was not adopted.
  • Copper and zinc balance while taking GHK-Cu — my results (opens in a new tab)lozzac_90 original post and same-author replies: 1.5 mg GLOW six days/week for two weeks, “uglies,” two-week pause, later separate GHK-Cu four nights/week, two lab dates and acknowledged missing pre-use baseline.Single self-report with zinc changes, GLOW/Wolverine co-use, changing dose and no pre-use copper/zinc baseline. Serum snapshots do not establish causality or intact-complex PK.
  • I want to try GHK-CU but I’m hesitant (opens in a new tab)Original question and visible first-person GLOW reply: first week described as wasp-sting pain, first one to two days lasting much of the day and night, then less frequent sensation after a month.One blend report with unverified product and no objective skin endpoint; reply includes preparation discussion that was not copied.

What people say 13

  • Skin firmness/texture: Firmer, smoother skin and fine-line talk over multi-week consistent use; photo reassess common at 8–12 weeks. forum
  • Tone / glow: “Healthier glow,” even tone, or post-procedure recovery look before big structural change. anecdote
  • Hair density: Thicker look or less shed over 12+ weeks topical/scalp use; minoxidil, needling, and other actives heavily confound attribution. forum
  • Hair trial talk: Some vendor/clinic summaries cite modest density/shaft-diameter gains over 6–12 months topical use — generally framed as weaker than minoxidil/finasteride standards. forum
  • Glow stack role: Framed as the skin/ECM remodeling leg next to BPC-157 (local repair lore) and TB-500 (systemic actin/migration lore). forum
  • Calmer / less reactive skin: Some report less irritated-looking skin during remodeling use; others hit copper uglies instead — outcome splits hard. forum
  • Soft-tissue adjacency: Injury stacks that add GHK-Cu often credit skin/scar quality more than tendon “feel.” anecdote
  • What logs rarely claim: Acute gym pumps, fat loss, or same-day “on” feeling — not a stimulant peptide. forum
  • Women vs men: Strongest published topical photoaging work is often in women. Injectable mg charts in 2026 are not a loud sex-split. Hair/scalp talk is mixed. trialforum
  • Topical collagen/clinical skin: Pickart-linked reviews cite thigh-skin collagen production improved in ~70% of women treated with GHK-Cu vs ~50% vitamin C cream and ~40% retinoic acid in comparative skin work. trial
  • Facial cream window: 12-week facial/eye cream work (often cited as ~71 women with photoaging) — density, thickness, laxity, clarity, fine lines vs vehicle in reviews. trial
  • Collagen / matrix hook: Type I collagen and ECM remodeling is the main science-facing claim; in-vitro fibroblast collagen stimulation at very low nanomolar ranges is widely repeated. lab
  • Wound & scar: Preclinical and wound-care literature (including hydrogel dressing contexts) cited for healing/remodeling; scar and post-procedure recovery talk is common in forums. animal

Doses people talk about 21

  • Injectable common window: ~0.5–2 mg subcutaneous per day; ~1–2 mg/day is the most repeated adult research-chem/clinic talk band. forum
  • Conservative start: ~0.5–1 mg/day SC while watching site reaction and early skin response. forum
  • Intensive / high logs: ~2–3 mg/day SC for aggressive skin/wound-style blocks; often debated as high and more linked to copper-uglies anecdotes. forum
  • Upper rarely cited: ~4 mg/day appears as an upper research/community ceiling in some guides — not a standard starting dose. forum
  • Non-daily / maintenance: ~1–2 mg SC 2–3× per week for skin maintenance with fewer needles. forum
  • 5-on / 2-off: Some anti-aging charts use daily SC on weekdays only (~1–2 mg) rather than 7×/week. forum
  • Escalation example (clinic-style writeups): ~1 mg/day for first ~15 days, then ~2 mg/day for next ~15 days inside a ~30-day block. forum
  • 1.7 mg/day figure: Commonly appears because Glow 5:1:1 blend math lands near ~1.7 mg GHK-Cu when total blend is ~2.3 mg/day. forum
  • Split dosing: Some split the daily total into morning + evening microdoses for “steadier levels” — preference talk, not trial-proven superiority. forum
  • Topical frequency: 1–2× daily standard; beginners sometimes start 2–3×/week or every other night. forum
  • Microneedling adjacency: Community caution to use lower strength on freshly needled skin (e.g. ~0.05% / ~500 ppm discussed) because absorption may rise ~10× — standard daily 0.1–1% serums on open channels are a common “uglies” story. forum
  • Glow blend (typical vial talk): ~70 mg total as 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 (≈ 5:1:1). Vendors vary. forum
  • Glow daily blend dose (guides): ~2.0–2.5 mg total blend SC once daily (often ~2.33 mg), delivering roughly ~1.7 mg GHK-Cu + ~0.33 mg BPC-157 + ~0.33 mg TB-500 per jab at 5:1:1. forum
  • KLOW blend (typical vial talk): ~80 mg total as 50 mg GHK-Cu + 10 mg KPV + 10 mg BPC-157 + 10 mg TB-500 (GLOW + KPV). Ratios still vendor-dependent. forum
  • Separate-vial style (when not pre-mixed): GHK-Cu ~1–2 mg/day; BPC-157 often ~250–500 mcg/day; TB-500 often front-loaded or multi-mg 1–2×/week rather than forced daily equal parts — pre-mix locks the ratio. forum
  • U-100 / blend-math fight: Solo 1–2 mg/day draws are one chart. Glow 5:1:1 daily ~2.3 mg total (~1.7 mg GHK) is another. People argue units because 50 mg GHK in a 70 mg vial plus mystery water does not match a 5 mg BPC “10 units = 250 mcg” screenshot. forum
  • Topical after-shower camp: Cleanse, slightly damp skin, serum, wait a couple minutes, then moisturizer. That is the non-pin dose culture — % on the bottle, not syringe ticks. forum
  • Topical % (consumer/clinic talk): ~0.1–2% GHK-Cu common on labels; many “effective consumer” writeups cluster ~1–2%. Higher % tracks with more irritation talk. forum
  • Uncertainty: Without third-party purity/fill tests, labeled blue-vial mg and blend ratios may not match; unit errors on multi-peptide vials are frequent. forum
  • Topical % (study band, as reviewed): Human cosmetic/skin studies are often summarized around ~0.01–1% (some secondary sources also cite up to ~1–4% formulations). Higher is not automatically better. trial
  • Framing: Community, clinic-marketing, and vendor protocol ranges only — not prescriptions, not medical advice, not proof of optimal dose. forum

How it may feel 10

  • Days 1–7 (topical): Mild tingle, tightness, or dryness possible; some notice softer feel by week 1–2. forum
  • Days 1–7 (injectable): Site responses vary from no reaction to warmth, sting, redness or a blue-tint mark. One recent account reported no reaction at 800 mcg, skin improvement by four weeks, then “copper uglies” after increasing to 1 mg; another reported pain lasting much of the first two days of a blend. forumanecdote
  • Weeks 2–4: Texture / “healthier skin” talk starts; copper-uglies window often lands here if strength, frequency, or needling absorption is high. forum
  • Copper uglies phase (if it hits): Community term for temporary dullness, breakouts, dryness, or “worse before better” look — often weeks ~2–5; many say it settles in ~4–6 weeks if dose/frequency/layering is cut. forum
  • Weeks 4–8: Firmness, fine lines, tone claims cluster; first serious photo comparisons. forum
  • Months 3–6: Hair and deeper remodel usually need this longer window; short 2-week runs are generally called underpowered for those goals. forum
  • No change ~8–12 wk: Check labeled strength/vehicle, consistency, photos (same light), purity, and stack confounds before dose-chasing. forum
  • First days vs week 2–4: Day 1 is sting, warmth, or a blue-tint mark more than a systemic kick. The “copper uglies” window — if it hits — is often weeks 2–5, not night one. Photos people trust are more like 8–12 weeks. forum
  • Bloodwork people mention: Serum copper, zinc, ceruloplasmin, and liver enzymes show up in 2026 GHK-monitoring posts — because it is a copper peptide, not because there is a proven “glow lab.” forum
  • Weeks 8–12: Matches many topical trial windows and early hair-density judgments; structural remodel talk peaks here for skin. trial

Around the dose 8

  • Clock: Daily. Topical AM or PM with skincare; injectable often morning with Glow/KLOW. forum
  • Training: Not pre-workout. Copper sting + training sweat is why people pin at home, not at the gym. forum
  • Topical habits: Clean skin. Stacking retinoid + acid + copper the same night is a common irritation combo. forum
  • Sun / skin: Skin logs still mention sunscreen and not picking at the area. forum
  • Consistency: Collagen/skin talk is daily votes, not a weekend catch-up dose. forum
  • Copper caution: Extra copper peptides on top of an already GHK-heavy blend is a frequent “why does this sting / why am I cycling off” thread. forum
  • Shower / cleanse first: Topical talk is after a shower or gentle cleanse, slightly damp skin, then GHK serum, wait ~1–5 minutes, then cream. Morning SPF still gets named. forum
  • Scalp: After shampoo, onto scalp not hair shaft, leave on — don’t rinse. Minoxidil is often split to the other time of day. forum

Cycles people discuss 10

  • Skin blocks (inject or topical consistency): ~4–8+ weeks before judging texture/firmness photos; many do not call skin until ~8–12 weeks. forum
  • Hair blocks: ~12–16 weeks minimum before density calls; some scalp protocols run 6–12 months topical. forum
  • Injectable on/off (solo): Common patterns include ~30 days on / ~14–30 days off; ~8 weeks on / ~8 weeks off; or ~4–8 weeks on with 2–4 weeks off. No single standard. forum
  • 5 days on / 2 off inside a 30–60 day window: Appears in wellness/anti-aging charts alongside continuous daily. forum
  • Glow cycles: Often ~4 weeks daily blend, then ~2–4 weeks off; longer aesthetic blocks ~6–8 or ~8–12 weeks also discussed. forum
  • KLOW cycles: Community guides often ~6–12 weeks on then a multi-week break (ratios vary widely). forum
  • Topicals: Frequently continuous with no formal off-period, or paused only for irritation/uglies. forum
  • Acute injury add-on: Shorter 10–14 day intensive inject talk exists in some stack guides, then reassess — thinner evidence than multi-week skin blocks. forum
  • Re-runs: Seasonal, pre-event aesthetic, or post-procedure restarts are common; long-term multi-year injectable safety data in healthy users is sparse. forum
  • Why cycle injectables at all: Cost, needle burden, copper-load caution, and thin chronic human SC data — not a proven “tolerance reset” law. forum

Timing 8

  • Plasma half-life (community shorthand): Posts often repeat ~30 minutes for GHK-related systemic exposure, but the reviewed evidence assessment identified no human PK characterization of intact GHK-Cu. Treat the number as unverified shorthand, not a measured dosing basis. forum
  • Other PK figures in circulation: ~2–4 hours and ~105 minutes after SC also circulate, but the reviewed sources do not establish their analyte, species, route or intact-complex assay. These figures conflict with the ~30-minute shorthand and cannot be merged into human GHK-Cu PK. forum
  • Why frequent dosing culture: Short blood duration is the usual rationale for daily (or multi-weekly) SC rather than weekly mega-doses. forum
  • Copper redistribution talk: Intact chelate may clear quickly while copper exchanges with albumin/tissue pools — used to explain “short PK, longer tissue story.” forum
  • Topical timing: Evening or 2× daily common; many separate strong acids, high-strength vitamin C, and retinoids into different slots or nights. forum
  • Inject timing: Bedtime, morning, or fixed daily clock all used; no rigorous head-to-head timing trials for aesthetic endpoints. forum
  • Glow timing: Once-daily SC for the blend is the dominant guide pattern even though TB-500 alone is often dosed less frequently when run separate. forum
  • Downstream lag: Skin/hair remodeling is discussed as gene/matrix biology that lags weeks after any single exposure — half-life ≠ time-to-photo-result. trial

More on what it is 11

  • Why people care: Skin firmness/texture, fine lines, hair density, wound/scar narratives, and as the “glow” leg of the Glow stack (GHK-Cu + BPC-157 + TB-500). forum
  • Research lens: Separate OTC/clinic topicals, peer-reviewed wound/skin work, and research-chemical inject vials. Online mg charts rarely match trial designs. forum
  • Molecule vs blend: Solo GHK-Cu is one peptide; Glow/KLOW pre-mixes force fixed ratios with BPC/TB (±KPV). forum
  • Not in the July 2026 PCAC peptide vote: BPC, KPV, and TB-500 were the Day-1 compounding votes. GHK-Cu was not on that ballot. People still file it under “FDA just approved peptides.” trialforum
  • Cosmetic cream ≠ research pin: OTC/clinic topicals and gray-market injectable vials are different products and different rules. forumtrial
  • What it is: Naturally occurring copper-binding tripeptide (Gly-His-Lys complexed with Cu²⁺), isolated from human plasma by Loren Pickart (1973). Also labeled copper tripeptide-1 in cosmetic INCI contexts. trial
  • Age decline (cited): Plasma GHK often quoted ~200 ng/mL around age 20 vs ~80 ng/mL by age 60 — used as the “why replace” story. trial
  • Evidence split: Stronger published human support for topical cosmetic/skin endpoints than for gray-market daily injectable anti-aging protocols. trial
  • Not: Not a steroid, not a GH secretagogue, not FDA-approved as a systemic injectable anti-aging drug. Cosmetic heritage ≠ proven injectable longevity protocol. trial
  • Injectable vs topical legal tracks: Non-injectable GHK-Cu was back in 503A Category 1 after a May 2026 nomination clarification. The injectable nomination was withdrawn. FDA said it intends to take GHK-Cu to PCAC before the end of February 2027. trial
  • Mechanism talk: Collagen/elastin/GAG and extracellular-matrix remodeling; dual MMP (clear damaged matrix) + TIMP (protect new matrix) framing; antioxidant and anti-inflammatory signaling; copper delivery to tissue. Often oversimplified in marketing. trial

Stacks 9

  • Glow stack (primary named stack): GHK-Cu + BPC-157 + TB-500 — aesthetic/recovery triad; common marketing ratio 5:1:1 (e.g. 50/10/10 mg). forum
  • KLOW stack: Glow + KPV (often 50 mg GHK-Cu + 10 mg each KPV/BPC/TB in 80 mg vials) for inflammation/gut-adjacent marketing on top of glow/repair. forum
  • Wolverine → Glow: BPC-157 + TB-500 injury core; GHK-Cu added when skin/scar/“look better while healing” is the goal. forum
  • Separate vials vs pre-mix: Separate allows independent BPC/TB/GHK schedules and dose cuts; pre-mix is convenience with locked ratios and harder purity attribution. forum
  • Topical skin routine: GHK-Cu serum + moisturizer + SPF; rotate or time-separate strong AHA/BHA, high-strength L-ascorbic acid, and retinoids to reduce sting and inactivation fights. forum
  • Hair stack confounds: Minoxidil, microneedling, finasteride/dutasteride, rosemary, other hair peptides (including AHK-Cu) — nearly impossible to isolate GHK-Cu credit. forum
  • Zinc balance talk: Long/high injectable copper-peptide runs often pair with zinc supplementation discussion (copper–zinc antagonism lore) — not a standardized trial protocol. forum
  • Basics that steal photo credit: Sleep, protein, sun protection, procedure aftercare, and retinoid history often explain “glow” as much as the vial. forum
  • Not usually stacked for: Same-syringe mix with random research chems outside documented blend SOPs — sterility and compatibility concerns dominate caution posts. forum

Access talk 5

  • Not on the July 23, 2026 ballot: PCAC that week voted BPC-157, KPV, TB-500, MOTS-c (then others the next day). GHK-Cu was a later, separate review. trialforum
  • Injectable nomination withdrawn: The pin is not the same 503A story as the cream. trialforum
  • Cosmetic vs RUO vs clinic: Drugstore copper serum, research-chem blue vials, and med-spa shots get sold under one nickname. forum
  • “FDA approved GHK” mix-up: Category-1 evaluation and a future PCAC date are not a drug approval. forumtrial
  • Non-injectable Category 1: After nominators withdrew and then clarified, FDA put GHK-Cu (except injectable routes) back in Category 1 and said it intends to consult PCAC before the end of February 2027. trial

Labs people mention 3

  • Copper panel talk: Serum copper, ceruloplasmin, and zinc are the labs 2026 GHK posts actually name. forum
  • Liver enzymes: CMP/ALT-AST gets bundled in “don’t ignore copper load” writeups. forum
  • Not a collagen blood test: People judge photos and sting, not a PICP/IGF number, in almost all logs. forum

Storage notes 4

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
  • Blue vial unit fight: Glow/KLOW pre-mixes make “how many units is 1 mg GHK?” depend on total milligrams in the vial and how much water went in. Solo GHK math is simpler than blend math. forum
  • Color change: Brown/green talk is treated as oxidized / toss-it, not “still fine.” forum

Watch for 13

  • Injection site: Redness, warmth, swelling, bruise, itch, lingering ache, or blue-tint mark — among the most reported practical issues; many call GHK-Cu a burning/stinging pin. forum
  • Copper uglies: Early dullness, breakouts, dryness, sensitivity, or “rapidly worse skin” look on strong topicals, high inject totals, or post-needling over-application. Documented as community lore and media-covered anecdote, not a formal diagnostic entity. forum
  • Uglies timing talk: Often weeks ~2–5 after start; community mitigation = lower %, less frequent use, stop needling stacking, pause other actives 2–4 weeks. forum
  • Layering fights: Same-routine AHA/BHA, high-strength vitamin C, benzoyl peroxide, or retinoids → sting, reduced tolerance, or blamed inactivation. forum
  • Microneedling overload: Open channels can multiply absorption; standard daily serum strength on fresh needles is a classic irritation/uglies path in guides. forum
  • Copper load / zinc balance: Higher chronic inject totals spark copper–zinc balance moderation chatter and “don’t ignore zinc” posts; formal toxicity data for DIY SC schedules is thin. forum
  • Systemic nonspecifics: Headache or malaise occasionally logged; hard to separate from stacks/illness. anecdote
  • Cancer / active malignancy caution: Remodeling/angiogenesis-adjacent talk leads many community and clinic writeups to treat active cancer history as a hard avoid for systemic research use. forum
  • Pregnancy / lactation: Little safety data for injectable research use — treated as avoid. forum
  • Oxidized product: Brown/green color change discussed as degraded copper peptide — discard talk, not “push through.” forum
  • Not risk-free: Decades of cosmetic/topical research ≠ safe gray-market daily multi-mg SC protocol. One clean log is not population safety. forum
  • Lumped into the 2026 peptide vote: GHK-Cu was not the July PCAC BPC/KPV/TB ballot. Injectable compounding status was still the separate, later-review story. forumtrial
  • Regulatory frame: Not an FDA-approved systemic anti-aging injectable; many products sold research-use-only. trial

Updated: 2026-09-01

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →